Simulations Plus (NASDAQ:SLP) Releases FY25 Earnings Guidance

Simulations Plus (NASDAQ:SLP) issued an update on its FY25 earnings guidance on Thursday morning. The company provided EPS guidance of $1.07-1.20 for the period, compared to the consensus EPS estimate of $1.09. The company issued revenue guidance of $90-93 million, compared to the consensus revenue estimate of $90.40 million.

Simulations Plus Stock Down 3.8 %

Shares of SLP traded down $0.95 during mid-day trading on Thursday, hitting $23.82. 352,825 shares of the company traded hands, compared to its average volume of 175,221. The company has a market capitalization of $478.59 million, a PE ratio of 59.55 and a beta of 0.89. The business has a 50 day moving average of $30.38 and a 200 day moving average of $30.38. Simulations Plus has a 1-year low of $23.00 and a 1-year high of $51.22.

Simulations Plus (NASDAQ:SLP) last posted its quarterly earnings results on Thursday, April 3rd. The technology company reported $0.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.25 by $0.06. The business had revenue of $22.43 million during the quarter, compared to analysts’ expectations of $21.93 million. Simulations Plus had a net margin of 10.97% and a return on equity of 6.84%. The business’s quarterly revenue was up 22.5% on a year-over-year basis. During the same quarter last year, the company posted $0.20 earnings per share. As a group, research analysts expect that Simulations Plus will post 1.09 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts recently commented on the company. William Blair reaffirmed an “outperform” rating on shares of Simulations Plus in a report on Wednesday, January 8th. KeyCorp lifted their price objective on shares of Simulations Plus from $35.00 to $37.00 and gave the company an “overweight” rating in a research note on Friday, January 24th. One research analyst has rated the stock with a sell rating, one has given a hold rating, five have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $49.40.

Insider Activity at Simulations Plus

In other Simulations Plus news, Director Walter S. Woltosz sold 20,000 shares of the company’s stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $33.91, for a total value of $678,200.00. Following the completion of the transaction, the director now owns 3,402,584 shares in the company, valued at approximately $115,381,623.44. This represents a 0.58 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 19.40% of the stock is owned by company insiders.

Simulations Plus Company Profile

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.